UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the month of June 2016
Commission File Number: 001-37569
STRONGBRIDGE BIOPHARMA plc
(Exact name of Registrant as specified in its charter)
900 Northbrook Drive
Suite 200
Trevose, PA 19053
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
On June 2, 2016, Strongbridge Biopharma plc (the “Registrant”) issued a press release announcing that Matthew Pauls, president and chief executive officer, is scheduled to present at the Jefferies 2016 Healthcare Conference, taking place June 7-10, 2016, in New York City.
The presentation will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com
The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.
Exhibits
Exhibit |
| Exhibit Table |
|
|
|
99.1 |
| Press Release issued by Strongbridge Biopharma plc, dated June 2, 2016. |